Title: THE METABOLIC SYNDROME A Reversible Life-Threatening Condition
1THE METABOLICSYNDROMEA Reversible
Life-Threatening Condition
- Metabolic Syndrome and Insulin Resistance
2Insulin Resistance (IR)
IS Insulin Sensitive Haffner SM et al. Diabetes
Care, 1999 22 562-568.
3IR as a CVD risk factor
Bonora E. et al., Diabetes Care 2002 25(7)
1135-1141.
4Risk of CVD rises as IR inceases
Hanley A.J. et al. Diabetes Care 2002 25
1177-1184. (San Antonio Heart Study)
5Glucometabolic effects of insulin
NEFA Non Esterified Fatty Acids
6Common insulin resistance (IR)
- underlies most cases of T2DM, central obesity and
metabolic syndrome - driven by overweight/obesity, as a result of
adipokines/FFA imbalance and lipotoxicity - represents a ? in insulin-mediated glucose uptake
(IMGU) and glycogen synthesis, mostly in skeletal
muscle (responsible for the bulk of IMGU) - Liver IR usually present, resulting from portal
adipokines/FFA imbalance and lipotoxicity
associated with fatty tissue expansion - IR is a continuous variable often considered
present when IMGU lt lower quartile of a normal
control cohort
Beck-Nielsen et al. in Insulin Resistance, Kumar
ORahilly eds. 2005 John Wiley Sons, Ltd
7Measuring Insulin Sensitivity ( Secretion )
- reciprocal of fasting plasma insulin (FPI -1)
- oral glucose tolerance test (OGTT)
- Intravenous glucose tolerance test (IVGTT)
- Homeostatic Model Assessment Continuous
Infusion of Glucose with Model Assessment
(HOMA-CIGMA) - Quantitative Insulin sensitivity ChecK Index
(QUICKI) - frequently sampled IVGTT with MinMod
- euglycemic hyperinsulinemic clamp (hyperglycemic
clamp) - glucose-insulin infusion
- Bonoras insulin tolerance test
- insulin suppression test
Various methods are currently used to assess
insulin sensitivity. The  gold standardÂ
euglycemic hyperinsulinemic clamp is used for
research purposes and pharmacological studies,
and is not applicable to large numbers. At the
opposite end, the reciprocal of fasting insulin
can be used in large scale epidemiological
studies in normal glucose tolerance subjects. In
subjects with impaired glucose tolerance or type
2 diabetes, methods that provide both beta cell
function estimates and insulin sensitivity (such
as HOMA) are often preferred and increasingly
used for routine testing.
8The next two slides illustrate two scenarios
linking obesity, insulin resistance and
components of the MetS
- the most common scenario starts from acquired
adipose tissue expansion in overweight-obese
individuals, with secondary muscle IR - another scenario starts from muscle IR and
intramyocellular fat accumulation, often
associated with mitochondrial dysfunction,
resulting in fat overflow in various organs,
including ectopic fat deposition - in predisposed individuals, the common scenario
sequence can coexist alongside genetic or
acquired defects in myocellular metabolism or
mitochondrial function, amplifying each other.
9(No Transcript)
10(No Transcript)
11Insulin Resistance (IR) and T2DM
- precedes hyperglycemia based in muscle/liver and
modulated by adipo-cytokines and NEFAs
originating from adipose tissue expansion - ? NEFAs availability induces ? in
intramyocellular long chain fatty acyl-CoA
(LCFAcyl-CoA), resulting in - ? insulin PIP3 PKB/Akt signaling
- ? glucose transport (GLUT4) / phosphorylation
- ? insulin-stimulated glycogen synthesis and
oxidative phosphorylation (ATP synthesis) - ? ectopic triglycerides (intramyocellular lipids
and intrahepatocytic lipids) - downregulation of PPARg coactivator-1 (PGC-1) and
PGC-1-controlled genes (mitochondrial biogenesis
and oxidative phosphorylation)
12Etiology of LCFAcyl-CoA pool expansion
upstreamof the mitochondria
- adipose tissue expansion and adipokine/FFA
imbalance - ? mitochondria number, size, function, or
combination - mutations (acquired or genetic) Mt DNA / or
Nucl DNA - ageing, drugs, oxidative stress
- fat overload (excess VLDL-C, dietary)
- decreased AMPK activity
- CPT-1 inhibition
- Young offspring of T2DM ? fibers IIb
Hereditary IR
13Insulin Resistance (IR) and T2DM
- any ? in intramyocellular lipids (IMCL) and
intrahepatocytic lipids (IHL) can cause IR - acquired and/or genetic mitochondrial dysfunction
(MD) and oxidation associated with IMCL and IHL
in subjects at risk for T2DM and in T2DM - abnormalities can combine MD ? ?
Intramyocellular Lipids Intrahepatic Lipids
(IMCL-IHL) ? ? lipid oxidation and IR, amplifying
each other (vicious cycle) - IR may start primarily as MD in genetic IR, or,
more commonly, from increased IMCL in
environmental-nutritional IR associated with
overweight-obesity - quantitative or qualitative sarcopenia secondary
to reduced anabolic-anticatabolic effects of
insulin in IR subjects
14Insulin Sensitivity (IS) x b-Cell Function (bCF)
definesa functional area that determines glucose
homeostasis
Adapted from Kahn SE, Prigeon RL, McCulloch DK,
Boyko EJ, Bergman RN, Schwartz MW, Neifing JL,
Ward WK, Beard JC, Palmer JP, et al.
Quantification of the relationship between
insulin sensitivity and beta-cell function in
human subjects. Evidence for a hyperbolic
function. Diabetes. 1993, 421663-72. Bergman RN,
Ader M, Huecking K, Van Citters G. Accurate
assessment of beta-cell function the hyperbolic
correction. Diabetes.2002, 51 Suppl 1S212-20.
Bergman RN. Pathogenesis and prediction of
diabetes mellitus lessons from integrative
physiology. Mt Sinai J Med. 2002, 69280-90.
15IS x bCF defines a functional area that
determinesglucose homeostasis
Adapted from Kahn SE, Prigeon RL, McCulloch DK,
Boyko EJ, Bergman RN, Schwartz MW, Neifing JL,
Ward WK, Beard JC, Palmer JP, et al.
Quantification of the relationship between
insulin sensitivity and beta-cell function in
human subjects. Evidence for a hyperbolic
function. Diabetes. 1993, 421663-72. Bergman RN,
Ader M, Huecking K, Van Citters G. Accurate
assessment of beta-cell function the hyperbolic
correction. Diabetes.2002, 51 Suppl 1S212-20.
Bergman RN. Pathogenesis and prediction of
diabetes mellitus lessons from integrative
physiology. Mt Sinai J Med. 2002, 69280-90.
16IS x bCF defines a functional area that
determinesglucose homeostasis
Adapted from Kahn SE, Prigeon RL, McCulloch DK,
Boyko EJ, Bergman RN, Schwartz MW, Neifing JL,
Ward WK, Beard JC, Palmer JP, et al.
Quantification of the relationship between
insulin sensitivity and beta-cell function in
human subjects. Evidence for a hyperbolic
function. Diabetes. 1993, 421663-72. Bergman RN,
Ader M, Huecking K, Van Citters G. Accurate
assessment of beta-cell function the hyperbolic
correction. Diabetes.2002, 51 Suppl 1S212-20.
Bergman RN. Pathogenesis and prediction of
diabetes mellitus lessons from integrative
physiology. Mt Sinai J Med. 2002, 69280-90.
17Hyperbolic relation between IS x bCF
Bonora E. et al. Diabetes Care, 2002 26 (7)
1153-1141.
1890 of T2DM IR and MS
Adapted from International Diabetes Center (IDC),
Minneapolis, Minnesota.